Novonesis A/s Class B · OMXCOP:NSIS_B
Novonesis A/s Class B — Novozymes — FY2022 Earnings Presentation
14 slides from Novonesis A/s Class B's earnings presentation, Jan 26, 2023
Slide 1: Conference call 12M 2022
Conference call 12M 2022 January 26, 2023
Slide 2: Forward Looking Statement
Disclaimer Forward Looking Statement This presentation and its related comments contain forward-looking statements, including statements about future events, future financial performance, plans, strategies and expectations. Forward-looking statements are associated with words such as, but not limite
Slide 3: Strong sales growth with solid earnings and returns
Strong sales growth with solid earnings and returns Sales and financial performance 2023 outlook • Organic 12M sales growth y/y: 9% (Q4 y/y: 11%). Reported DKK sales growth: 17% • 4-7% organic sales growth with growth across all business areas. (Q4 y/y: 18%). Pricing expected to account for more tha
Slide 4: Household Care
Household Care 2023 expectations Performance in line with expectations • Organic 12M sales growth y/y: 1% (Q4 y/y: 4%). • Growth driven by pricing, innovation • Growth in line with expectations, driven by penetration in and . increased emerging markets, including the negative impact from the 28% pen
Slide 5: Food, Beverages & Human Health
Food, Beverages & Human Health 2023 expectations Strong performance across all subareas • Growth to be broad • Organic 12M sales growth y/y: 10% (Q4 y/y: 16%). based, driven by Food and Human Health. • Growth in Food was broad-based, driven by innovation, optimization of raw materials and penetratio
Slide 6: Bioenergy
Bioenergy Strong performance driven by innovation and 2023 expectations penetration • Assumes U.S. • Organic 12M sales growth y/y: 25% (Q4 y/y: 22%). ethanol production 21% flat to slightly down • Growth mainly driven by innovation in North America, supported by compared to 2022. recovering U.S. eth
Slide 7: Grain & Tech Processing
Grain & Tech Processing 2023 expectations Strong performance led by grain • Growth driven by • Organic 12M sales growth y/y: 10% (Q4 y/y: 5%). pricing and Grain led by market penetration • Double-digit growth in Grain driven by strong underlying in vegetable oil end-market demand and innovation. 15%
Slide 8: Agriculture, Animal Health & Nutrition
Agriculture, Animal Health & Nutrition Solid performance driven by Animal Health & 2023 expectations Nutrition • Organic 12M sales growth y/y: 8% (Q4 y/y: 11%). • Growth will be broad-based, 12% driven by pricing, • Performance driven by strong growth in Animal Health & Nutrition and solid performan
Slide 9: Financial results 2022
Financial results 2022 • Organic sales growth 2022 y/y: 9%; DKK sales 17% y/y. • Gross margin at 54.6%; 3.1pp lower than last year due to higher input, energy and logistics costs, partly mitigated by productivity improvements, operational leverage and pricing. Q4 gross margin impacted by negative mi
Slide 10: Financial outlook 2023
Financial outlook 2023 • Organic sales growth of 4-7% with sales in reported DKK roughly 2 percentage points lower. • EBIT margin before special items* outlook of 25-26%. • ROIC** before special items* expected at 16-17%. 2023 Outlook *** Sales performance, organic % 4-7 EBIT margin before special i
Slide 11: Nonfinancial milestones and targets
Nonfinancial milestones and targets Targets & commitments 2025 Milestones Long-term Reduce absolute CO2 emissions 65% from operations 75% from operations by 2030 Climate 35% from supply chain by 2030 Purchase renewable electricity 100% Net-zero by 2050 Restore water in basins close to our production
Slide 12: A 'better together' gamechanger – with increased value creation opportunity
A ‘better together’ gamechanger – with increased value creation opportunity Complementary strengths of each business leveraged to create a leading global biosolutions partner with a diversified biological toolbox Global megatrends and industry tailwinds support ‘stronger together’ rationale Strong i
Slide 13: Cost and revenue synergies drive significant near-term value creation
Cost and revenue synergies drive significant near-term value creation Overview of synergies Run-rate EBIT contribution % Share (cost) • Production optimisation • Repair and maintenance and consumables efficiencies COGS ~40 - 50% COGS (of total) • Procurement savings from contract bundling and logist
Slide 14: Summary
Summary • Strong and broad-based growth with solid earnings and returns in a difficult environment. • Clear benefits from the set agenda ‘Unlocking growth – powered by biotech’. • 2023 outlook includes stronger pricing as well as volume growth. • Continuing the strategic journey with the proposal to